Novartis slides as Q1 results miss estimates amid Entresto generic pressure
Novartis shares are down after first-quarter 2026 results missed expectations, pressured by U.S. generic erosion of Entresto. The company reaffirmed full-year 2026 guidance, but investors are focusing on near-term sales and profit headwinds tied to the patent cliff.
1. What’s moving the stock
Novartis (NVS) is trading lower after reporting first-quarter 2026 results that came in below market expectations, with management citing pressure from generic competition—most notably impacting U.S. growth for Entresto. The miss is driving a reset in near-term expectations even as the company kept its full-year 2026 guidance unchanged.
2. Key numbers investors are reacting to
In the quarter ended March 31, 2026, Novartis reported core operating profit of about $4.9 billion, below the roughly $5.1 billion level expected by analysts, alongside softer sales versus consensus forecasts. The company also posted core EPS of $1.99, reflecting year-over-year pressure as generic erosion weighed on results.
3. Guidance and the bigger debate: patent cliff vs. pipeline
Novartis reiterated its FY 2026 guidance, signaling confidence that brand momentum and launches can help stabilize performance despite near-term generic headwinds. Still, today’s move reflects investor concern that the most immediate impact from the patent cliff is arriving faster than hoped, making upcoming second-half clinical readouts and pipeline milestones more critical to the stock’s narrative.